Medicare Part B Step Therapy Mitotic Inhibitors
Customize your policy alerts
Sign up for zing_health Policy 5858-D alerts
Get alerted when Policy 5858-D changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of preferred and non-preferred mitotic inhibitor products under Medicare Part B Advanced Biosimilars First. Non-preferred Abraxane requires prior authorization and a clinical exception for treatment of an FDA-approved indication of a preferred product.
No material clinical or coverage changes in this revision.
Non-Preferred Product Clinical Exception
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.